1253915-37-5

Basic information

• Product Name: 2-(2,4-dichlorophenyl)-8-((2-(naphthalen-1-yl)ethyl)sulfonyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one
• Synonyms: 2-(2,4-dichlorophenyl)-8-((2-(naphthalen-1-yl)ethyl)sulfonyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one
• CAS NO: 1253915-37-5
• Molecular Weight: 516.448
• Mol File: 1253915-37-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(2,4-dichlorophenyl)-8-((2-(naphthalen-1-yl)ethyl)sulfonyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,4-dichlorophenyl)-8-((2-(naphthalen-1-yl)ethyl)sulfonyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one(1253915-37-5)
• EPA Substance Registry System: 2-(2,4-dichlorophenyl)-8-((2-(naphthalen-1-yl)ethyl)sulfonyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one(1253915-37-5)

Safety Data

• Hazardous Substances Data: 1253915-37-5(Hazardous Substances Data)

Upstream product

• 89-75-8 2,4-dichlorobenzoyl chloride 
• 104296-63-1 2-(naphthalen-1-yl)ethane-1-sulfonyl chloride 
• 1253923-97-5 tert-butyl 2-(2,4-dichlorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate 
• 1253923-96-4 tert-butyl 4-cyano-4-(2,4-dichlorobenzamido)piperidine-1-carboxylate 
• 331281-25-5 4-amino-4-cyano-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism

During the course of derivatization of HTS hit 4a, we have identified a novel small-molecule hPTHR1 agonist, 1-(3,5-dimethyl-4-(2-((2-((1R,4R)-4-methylcyclohexyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-1-methylurea (CH5447240, 14l). Compound 14l exhibited a potent in vitro hPTHR1 agonist effect with EC20 of 3.0 μM and EC50 of 12 μM and showed excellent physicochemical properties, such as high solubility in fasted state simulated intestinal fluid and good metabolic stability in human liver microsomes. Importantly, 14l showed 55% oral bioavailability and a significantly elevated serum calcium level in hypocalcemic model rats.